WSNYSEBasic Materials

WORTHINGTON STEEL INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$40.66

-3.40%

Alpha Vantage · 10/30/2026

Industry: SteelCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze WS free

One-year price history

Adjusted daily closes · 252 observations · as of Oct 30, 2026

Historical data, not a forecast

1 month

+11.9%

3 months

+12.2%

6 months

+4.7%

1 year

+31.9%

Year to date

+19.1%

52-week range

$27.86 – $48.04

Fundamental snapshot

Latest reported period: Aug 31, 2026

Sharadar reported data

Market cap

$2.08B

P/E

-54.4

P/B

P/S

0.4

Revenue

$5.3B

Net income

-$38.3M

Diluted EPS

-0.76

Gross margin

10.40%

Net margin

-0.70%

Return on equity

-3.50%

Total debt

$2.59B

Cash

$248.2M

Free cash flow

$46.7M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Aug 31, 2026	$2.73B	-$10M	9.60%	-0.40%	-$69M
May 31, 2026	$929.2M	-$57.5M	12.80%	-6.20%	$7.8M
Feb 28, 2026	$769.8M	$10.4M	9.90%	1.40%	$33.3M
Nov 30, 2025	$871.9M	$18.8M	10.70%	2.20%	$74.6M
Aug 31, 2025	$872.9M	$36.8M	13.20%	4.20%	-$35.7M
May 31, 2025	$832.9M	$55.7M	15.20%	6.70%	$8.4M
Feb 28, 2025	$687.4M	$13.8M	11.80%	2.00%	$25.2M
Nov 30, 2024	$739M	$12.8M	10.80%	1.70%	$33.2M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent WS news

All market news

Dealroom·Oct 28, 202652 signal

West Pharmaceutical draws $200M term loan in $950M refinancing

West Pharmaceutical Services has secured a new $950 million unsecured credit facility, including a $200 million term loan and a $750 million revolving credit line, with Bank of America as the administrative agent. This refinancing replaces their 2019 credit agreement and aims to provide liquidity for working capital, acquisitions, stock repurchases, and debt repayment. The move reflects the company's strong sales growth and continued investment in injectable drug delivery capacity.

Original source